Chronic Kidney Disease Stages Statistics in US 2026 | Key Facts

What are the Chronic Kidney Disease Stages ?

Chronic kidney disease (CKD) stands as one of the most underdiagnosed and underdiscussed public health crises sweeping across the United States today. In 2026, the weight of this condition continues to press heavily on millions of American families, healthcare systems, and federal budgets — yet a staggering 9 in 10 adults with CKD do not even know they have it. CKD is defined as a progressive, long-term deterioration of kidney function that persists for at least three months, ultimately impairing the kidneys’ ability to filter waste, regulate fluids, and maintain chemical balance in the blood. The disease is classified across five distinct stages based on the estimated glomerular filtration rate (eGFR) — a laboratory measure of how effectively the kidneys are filtering blood per minute. Stage 1 (Normal or High Kidney Function with Damage Markers) is where eGFR sits at 90 or above with signs of kidney damage such as protein in the urine, yet most patients feel completely fine. Stage 2 (Mildly Reduced Kidney Function) sees eGFR between 60 and 89, again with damage markers present but still largely symptom-free. Stage 3 (Mild to Moderately Reduced Kidney Function) — split into Stage 3a (eGFR 45–59) and Stage 3b (eGFR 30–44) — is where fatigue, fluid retention, and early complications like anemia and bone disease may begin to surface. Stage 4 (Severely Reduced Kidney Function) brings eGFR down to 15–29, placing patients on the doorstep of kidney failure and requiring urgent nephrology care and preparation for renal replacement therapy. Finally, Stage 5 (End-Stage Kidney Disease or Kidney Failure) is reached when eGFR drops below 15, representing near-total kidney failure and requiring dialysis or a transplant to sustain life.

What makes the chronic kidney disease stages in America in 2026 especially alarming is not just the sheer scale — an estimated 35.5 million Americans are living with CKD — but the silent, symptom-free nature of the disease’s early stages that allows it to advance unchecked for years. The two dominant drivers of CKD in the United States are diabetes and high blood pressure (hypertension), together accounting for roughly two-thirds of all new kidney failure cases. These underlying conditions are themselves highly prevalent in American society, creating a cascading public health emergency that disproportionately affects older adults, racial and ethnic minorities, and those in lower income brackets. Understanding the stages of CKD, the populations most at risk, and the economic toll this disease exacts on the nation is not just medically essential — it is a civic priority for anyone engaged with where America’s health is heading.

Interesting Key Facts: Chronic Kidney Disease Stages in the US 2026

Source: CDC Chronic Kidney Disease in the United States, 2023; USRDS 2023 and 2024 Annual Data Reports; NIDDK Kidney Disease Statistics; National Kidney Foundation, 2024

Chronic kidney disease stages in the United States paint a picture that demands serious national attention. The fact that 35.5 million Americans — roughly 1 in 7 adults — are estimated to be living with CKD as of the latest surveillance data is staggering on its own. But what elevates this from a medical statistic to a public health emergency is the near-total lack of awareness among those affected: 9 in 10 adults with CKD do not know they have the condition, and even among those in the severe Stage 4 category, roughly 1 in 3 remains undiagnosed. This is not a failure of medicine alone — it is a failure of early screening culture, health literacy, and proactive care systems, particularly among populations who face systemic barriers to access.

Perhaps even more striking are the racial disparities embedded in these numbers. Non-Hispanic Black adults account for 20% of CKD prevalence — significantly higher than White or Hispanic populations — and are over four times more likely than White Americans to progress to ESKD. This disparity is partly explained by the higher rates of hypertension and diabetes within Black communities, as well as genetic factors like the APOL1 gene risk variants. Meanwhile, more than 808,000 Americans are already living with ESKD, with 68% dependent on dialysis — a life-sustaining but costly and grueling treatment — while only 32% have received a kidney transplant. With 90,323 people on the transplant waiting list as of late 2024 and only 27,332 transplants completed in all of 2023, the gap between supply and need is sobering, and the human cost of that gap is immeasurable.

CKD Prevalence by Stage in the US 2026 – Chronic Kidney Disease Stages Statistics

Source: CDC CKD Surveillance System (NHANES 2017–March 2020); USRDS 2023 Annual Data Report; CDC Chronic Kidney Disease in the United States, 2023

When you look at the chronic kidney disease stage-by-stage breakdown across the United States, what becomes immediately clear is that the burden of this disease is overwhelmingly concentrated in its earlier, largely invisible stages. Stages 1 through 3 together represent the vast majority of CKD cases in the country — most of which go undetected, untreated, and unacknowledged. The overall crude prevalence of CKD across all stages was measured at 13.9% during the 2017–March 2020 NHANES cycle, compared to 12.9% during 2001–2004, indicating a slow but persistent rise over two decades. While the age-standardized trends show greater nuance — suggesting some demographic stabilization at certain stages — the raw numbers convey that America’s CKD burden is growing with its aging and increasingly diabetic population.

Stage 4 CKD is where clinical management becomes especially critical. With kidney function down to just 15–29% of normal capacity, patients at this stage face imminent risk of crossing into full kidney failure. Yet approximately 1 in 3 people at this severe stage still do not know they have CKD — a fact that speaks volumes about the limitations of routine health screening in the United States. By contrast, Stage 5 (ESKD) is almost always diagnosed because it requires immediate treatment in the form of dialysis or transplantation. The 808,000 Americans living with ESKD represent the smallest but most medically intensive and costly segment of the CKD population, and their numbers have only grown as the underlying risk factors of diabetes and hypertension continue to pervade American life.

CKD by Age Group in the US 2026 – Chronic Kidney Disease Age Statistics

Source: CDC Chronic Kidney Disease in the United States, 2023 (NHANES 2017–March 2020 data); NIDDK Kidney Disease Statistics for the United States, updated 2024

The relationship between age and chronic kidney disease stages in the US is among the most consistent findings across decades of kidney health research. The data confirms that CKD prevalence triples as Americans move from the 18–44 age bracket (6%) to the 45–64 range (12%), and then nearly triples again in the 65-and-older population (34%). Kidney function naturally declines with age — the glomerular filtration rate decreases by roughly 1 mL/min/year after the age of 40 — but that age-related decline is dramatically accelerated when combined with conditions like diabetes, hypertension, and cardiovascular disease, which are themselves far more common in older Americans. The aging of the US population, driven by the Baby Boomer generation, means the national CKD burden is structurally poised to grow in the years ahead even if risk factor management improves.

What makes the 45–64 age group particularly significant from a public health strategy standpoint is that this is the window during which intervention remains most impactful. At this age, CKD is often in Stage 2 or 3 — stages where lifestyle modifications, medication, and close monitoring can meaningfully slow or halt disease progression. Yet the 12% prevalence figure at this age group also reflects how many Americans are entering their older years with already-damaged kidneys, setting the stage for the dramatic 34% burden seen in those over 65. Targeted screening programs, routine eGFR testing at annual physicals, and blood pressure and glucose management for adults in midlife are among the most cost-effective tools available to reduce the looming wave of late-stage CKD that America’s aging demographics are bringing.

CKD by Race and Ethnicity in the US 2026 – Chronic Kidney Disease Racial Disparity Statistics

Source: CDC Chronic Kidney Disease in the United States, 2023; USRDS 2023 Annual Data Report; NIDDK Kidney Disease Statistics, updated 2024

Racial and ethnic disparities in chronic kidney disease stages in the United States are not incidental — they are deeply structural, reflecting generations of unequal access to healthcare, disproportionate exposure to chronic disease risk factors, and in some cases, genetic predispositions that interact with environmental stressors. Non-Hispanic Black adults carry the heaviest burden, with a 20% CKD prevalence rate — significantly higher than White Americans (12%) — and a fourfold elevated risk of progressing to end-stage kidney disease. Black Americans make up approximately 14% of the total US population, yet they account for 30% of all ESKD cases in the country. A significant portion of this disparity is linked to the APOL1 gene, a genetic variant carried by approximately 13% of Black Americans that is strongly associated with faster kidney disease progression and a higher risk of focal segmental glomerulosclerosis and HIV-associated nephropathy.

The disparities extend well beyond Black Americans. Hispanic and Native American adults are each twice as likely as White Americans to develop ESKD, driven largely by the exceptionally high rates of Type 2 diabetes within these communities. Since 2001, the number of Hispanic, Native Hawaiian and Other Pacific Islander, and Asian people with kidney failure has more than tripled in each of these racial/ethnic groups — a striking trend that underscores how the expansion of diabetes and obesity across diverse American communities is translating directly into a growing ESKD crisis. Addressing these disparities requires not just improved clinical care, but upstream solutions: culturally competent outreach, expanded Medicaid coverage, and targeted screening programs in high-risk communities.

CKD Risk Factors in the US 2026 – Chronic Kidney Disease Causes & Risk Statistics

Source: CDC Chronic Kidney Disease in the United States, 2023; USRDS 2023 Annual Data Report; National Kidney Foundation Fact Sheet, 2024; NIDDK Kidney Disease Statistics

The risk factors driving chronic kidney disease stages in the United States in 2026 are, at their core, largely preventable or manageable — which makes the scale of the crisis all the more frustrating. Diabetes is the leading cause of CKD, affecting 38.5% of all diabetic adults with some degree of kidney damage, and is the primary driver behind 38% of all new ESKD cases annually. Hypertension, the second leading cause, affects 24.6% of hypertensive adults with CKD and drives an additional 27% of ESKD incidence. Together, these two conditions — both of which are intimately linked to diet, lifestyle, weight, and access to preventive care — are responsible for nearly two-thirds of all new kidney failure cases in the country. The fact that approximately 42% of US adults are obese (a powerful accelerant of both diabetes and hypertension) means the pipeline for future CKD cases is, unfortunately, robust.

The interplay between risk factors creates a compounding danger that clinical data only partially captures. An individual who is obese, hypertensive, and diabetic does not face simply additive CKD risk — the conditions interact synergistically, accelerating kidney damage through multiple pathways including oxidative stress, inflammation, vascular damage, and glomerular hyperfiltration. Tobacco smoking, while its prevalence is declining in the US, remains a significant independent CKD risk factor by damaging the renal vasculature. Family history — particularly carrying two copies of the APOL1 high-risk allele — raises the risk of certain kidney diseases more than tenfold in Black Americans. The interconnected nature of these risk factors calls for comprehensive, multi-condition management programs rather than organ-by-organ treatment approaches.

ESKD Treatment & Transplant Statistics in the US 2026 – End-Stage Kidney Disease Data

Source: USRDS 2023 and 2024 Annual Data Reports; US Organ Procurement and Transplantation Network (OPTN), updated October 2024; NIDDK Kidney Disease Statistics

The end-stage kidney disease treatment landscape in the US tells a story of medical progress shadowed by system-level shortfalls. On one hand, the adjusted ESKD incidence rate has declined by a meaningful 18.6% over the past decade (2012–2022), reflecting the impact of better management of diabetes and hypertension, improved pharmacological options, and evolving clinical guidelines. On the other hand, the 808,000+ Americans currently living with ESKD represent the accumulated burden of years of under-screened, under-managed earlier-stage CKD — and the treatment options available to them are costly, demanding, and in the case of transplantation, deeply constrained by organ supply. With 90,323 people on the kidney transplant waitlist and only 27,332 transplants performed in all of 2023, the math is stark: the majority of those waiting will either die waiting, remain on dialysis indefinitely, or wait many years before receiving a life-changing organ.

The mortality gap between dialysis and transplant patients is perhaps the most compelling argument for expanding transplant access. Dialysis patients face a mortality rate of 187.7 per 1,000 person-years, compared to just 74.3 per 1,000 person-years for kidney transplant recipients — meaning a transplant recipient has dramatically better survival odds than someone kept alive on dialysis. Children with ESKD fare far better in terms of transplant access than adults — 85.4% receive a transplant within five years of being waitlisted, compared to between 28.5% and 55.3% for adults depending on age group. Among waitlisted adults, females are slightly more likely than males to receive a transplant within five years (47.9% vs. 45.3%), but racial disparities persist, with Native Hawaiian/Pacific Islander patients having the lowest five-year receipt rate at 41.0%.

CKD Healthcare Costs in the US 2026 – Economic Burden of Chronic Kidney Disease Stages

Source: USRDS 2023 Annual Data Report; NIDDK Kidney Disease Statistics, updated 2024; AJMC Medical Costs for CKD study; CMS ESRD PPS Final Rule, 2024

The economic cost of chronic kidney disease stages in the United States in 2026 is not just enormous — it is arguably one of the single largest drivers of unsustainable Medicare expenditure in the country. Medicare spending on CKD patients ages 66 and older reached nearly $77 billion in 2021, representing 24.1% of all Medicare expenditure in that age group — a figure that outpaces spending on almost every other chronic condition. Perhaps more jarring is the per-person comparison: a Medicare beneficiary aged 66 or older with CKD costs the program $28,162 per year, compared to just $13,604 per year for a comparable beneficiary without CKD — meaning CKD patients cost more than twice as much to insure. When ESKD-related spending is added ($52.3 billion in 2021), the combined kidney disease Medicare burden exceeds $129 billion annually — a figure that dwarfs the GDP of many smaller nations.

Breaking the cost down by CKD stage reveals why early detection and intervention are economically as well as medically rational. Managing a patient in Stage 1–2 costs an estimated $7,725 over four months — manageable with medications, lifestyle adjustments, and monitoring. By Stage 5 without dialysis, that cost rises to $11,879. Once a patient requires dialysis, the acute cost spikes to $87,538 in the first four months alone, with ongoing annual dialysis costs ranging from $87,000 to $99,000 per patient per year. A kidney transplant, while more expensive upfront at $124,271 for the first four months, becomes significantly more cost-effective over the long term because transplant patients have lower mortality, reduced dialysis dependency, and improved quality of life. The economics alone make a compelling argument for the kind of prevention, early screening, and transplant access investments that the US healthcare system has yet to fully embrace.

CKD Awareness & Diagnosis Gaps in the US 2026 – Chronic Kidney Disease Detection Statistics

Source: CDC Chronic Kidney Disease in the United States, 2023; NIDDK Kidney Disease Statistics; National Kidney Foundation Fact Sheet, 2024; CDC National Center for Health Statistics

The chronic kidney disease awareness gap in the United States is not a minor data point — it is the central obstacle to reducing the nation’s CKD burden. The fact that 9 in 10 Americans living with CKD do not know they have it means that for the overwhelming majority of the 35.5 million affected adults, the disease is progressing silently, undisturbed by lifestyle intervention, medication, or medical monitoring. The reasons are well-documented: early CKD stages (1 through 3) produce virtually no symptoms. Fatigue, swelling, and changes in urination — the most common early signals — are easily attributed to other causes, especially in a culture not accustomed to routine kidney function testing. Two simple, inexpensive tests — a blood test for eGFR and a urine test for albumin — can detect CKD early, yet these remain inconsistently ordered during routine primary care visits, particularly for patients who have not yet been flagged with diabetes or hypertension.

The breakdown of awareness by race is both revealing and deeply concerning. Black Americans, despite having the highest CKD prevalence of any racial group, have the highest awareness rate among CKD patients — yet that rate stands at only 12%, still leaving nearly nine in ten undiagnosed. Among Hispanic Americans, only about 6% of those living with CKD are aware of their condition — the lowest awareness rate among major racial groups, even as Hispanics face twice the risk of progressing to ESKD compared to White Americans. CKD is currently the 9th leading cause of death in the United States, claiming approximately 57,937 lives per year — more than breast cancer or prostate cancer — yet it receives a fraction of the public health attention or research investment dedicated to those conditions. Closing the awareness gap through widespread, systematic kidney screening is not just a clinical imperative; it is a matter of health equity and national urgency.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE